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Abstract: Osteoporosis most commonly affects postmenopausal women, placing them at a 
signiﬁ  cant risk of fractures. In particular, hip fractures are an important cause of mortality and 
morbidity among postmenopausal women. Anti-resorptive therapies that produce greater decreases 
in bone turnover markers together with greater increases in bone mineral density (BMD) are 
associated with greater reductions in fracture risk, especially at sites primarily composed of corti-
cal bone such as the hip. Thus, treatment with potent anti-resorptive drugs like alendronate is a 
strategy for preventing hip fractures in postmenopausal women with osteoporosis. The purpose 
of this paper is to discuss the efﬁ  cacy of alendronate against hip fractures and the mechanism 
for this anti-fracture efﬁ  cacy in postmenopausal women with osteoporosis. A meta-analysis of 
randomized controlled trials has shown that alendronate reduces the risk of hip fractures by 
55% in postmenopausal women with osteoporosis. According to the analyses of the Fracture 
Intervention Trial, each 1 standard deviation reduction in a 1-year change in bone-speciﬁ  c 
alkaline phosphatase (BSAP) is associated with 39% fewer hip fractures in alendronate-treated 
postmenopausal women, and those with at least 30% reduction in BSAP have a 74% lower risk 
of hip fractures relative to those with less than 30%. Alendronate is effective in reducing the risk 
of hip fractures across a spectrum of ages. The mechanism for this anti-fracture efﬁ  cacy has been 
clariﬁ  ed; alendronate strongly suppresses bone turnover and subsequently increases hip BMD, 
decreases cortical porosity, improves parameters of hip structure geometry (cortical thickness, 
cross-sectional area, section modulus, and buckling ratio), and produces more uniform miner-
alization (increases the mean degree of mineralization of bone) in cortical bone. A once-weekly 
regimen of alendronate administration provides better patient compliance and persistence with 
the treatment than the once-daily dosing regimen, leading to greater efﬁ  cacy against hip fractures. 
Thus, the efﬁ  cacy of alendronate against hip fractures has been conﬁ  rmed in postmenopausal 
women with osteoporosis, especially with a once-weekly dosing regimen.
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Introduction
Osteoporosis most commonly affects postmenopausal women, placing them at a sig-
niﬁ  cant risk of fractures. In particular, hip fractures are an important cause of mortality 
and morbidity among postmenopausal women. Approximately 20% of patients with hip 
fractures die within a year, most of the deaths occurring within the ﬁ  rst 6 months after 
a fracture (Cumming et al 1997). Among the survivors, 30%–50% never regain their 
prefracture functional status (Cooper et al 1993). Therefore, healthcare expenditure 
attributable to hip fractures is substantial.
Recent reports have shown that the rate of hip fractures is falling in Ontario and 
Finland (Jaglal et al 2005; Kannus et al 2006), probably because of recent indications that 
clinical attention to osteoporosis management is increasing and that speciﬁ  c programs of Clinical Interventions in Aging 2008:3(3) 484
Iwamoto et al
selective screening and aggressive treatment to prevent bone 
loss may really be able to reduce the fracture rate among the 
population most at risk (Melton et al 2005). However, there 
is no indication that the use of effective osteoporosis inter-
ventions is increasing dramatically in regions including Asia 
where the growth in the elderly population is most rapid.
Because elevated bone turnover markers and low bone min-
eral density (BMD) are independent predictors of hip fracture 
risk, and the risk is multiplied when both are present (Garnero 
et al 1996), bone turnover and BMD are important factors in 
decreasing the risk of hip fractures. Both reduction in bone turn-
over and increase in hip BMD may be necessary to decrease the 
fracture risk of the hip, which is primarily composed of cortical 
bone and may require greater proportionate changes than trabecu-
lar bone (Epstein 2007). In fact, drugs with a smaller effect on 
bone turnover reduce the risk of only vertebral fractures, whereas 
those with a greater effect reduce the risk of both vertebral and 
nonvertebral fractures including hip fractures (Delmas 2002). 
Furthermore, only those drugs associated with relatively large 
BMD increases together with greater reductions in bone turnover 
were effective for reducing the risk of nonvertebral fractures 
including hip fractures (Hochberg et al 2002).
Treatment with potent anti-resorptive drugs is a strategy 
for preventing hip fractures in postmenopausal women. 
Several therapeutic agents are currently available to treat or 
prevent postmenopausal osteoporosis (Iwamoto et al 2006, 
2007). Among commercially available drugs, however, only 
alendronate, risedronate, intravenous zoledronate, strontium 
ranelate, and hormone replacement therapy (HRT) have 
shown anti-fracture efﬁ  cacy against hip fractures in post-
menopausal women (Black et al 1996, 2007; McClung et al 
2001; Rossouw et al 2002; Reginster et al 2005). Alendronate 
and risedronate, which are the second- and third-generation 
bisphosphonates, respectively, have been used as ﬁ  rst-line 
drugs in the treatment of osteoporosis for many years. In 
particular, evidence to explain the efﬁ  cacy of alendronate 
against hip fractures has been accumulated for postmeno-
pausal osteoporosis. Thus, this paper discusses, based on a 
review of the literature, the efﬁ  cacy of alendronate against 
hip fractures and the mechanism for this anti-fracture efﬁ  cacy 
in postmenopausal women with osteoporosis.
Efﬁ  cacy of alendronate against 
hip fractures in postmenopausal 
women with osteoporosis
Treatment of osteoporosis is conducted in accordance with 
the principles of evidence-based medicine (EBM). EBM 
takes into account information derived from the highest-
quality investigations with clinical judgment and patient 
values, to allow optimal clinical management. All available 
clinical evidence is classiﬁ  ed hierarchically into various lev-
els; strictly conducted systematic reviews with homogeneity 
represent the highest level, followed by strictly conducted 
randomized controlled trials (RCTs) with narrow conﬁ  dence 
interval or meta-analyses with homogeneity of RCTs, which 
have long been considered as the “gold standard” in the 
context of clinical investigations (Centre for Evidence Based 
Medicine). The important points that must be considered in 
the choice of drugs for the treatment of osteoporosis are the 
effects of the drugs in reducing the incidence of fractures, 
the consistency of the results of RCTs of the drugs, and the 
long-term efﬁ  cacy and safety of the drugs.
A meta-analysis conducted by Papapoulos et al (2005) 
demonstrated the efﬁ  cacy of alendronate against hip frac-
tures in postmenopausal women with osteoporosis. In total, 
6,804 women with BMD T-score of –2.5 or less (age range: 
39–91 years) from 6 RCTs were analyzed. The rates of hip 
fractures were 29 per 10,000 person-years at risk (PYR) 
in the alendronate group and 62 PYR in the control group. 
The overall risk reduction rate was 55% with the consistent 
results of RCTs (Figure 1). Reductions in risk of hip frac-
tures with alendronate treatment were consistent across all 
studies. The efﬁ  cacy of alendronate against hip fractures in 
Figure 1 Meta-analysis of the efﬁ  cacy of alendronate against hip fractures in post-
menopausal women with osteoporosis.  A meta-analysis conducted by Papapoulos et al 
(2005) demonstrated the efﬁ  cacy of alendronate against hip fractures in postmeno-
pausal women with osteoporosis who were naïve to bisphosphonate treatment. In 
total, 6,804 women with BMD T-score of –2.5 or less (age range: 39–91 years) from 6 
multicenter RCTs were analyzed. The rates of hip fractures were 29 per 10,000 PYR 
in the alendronate group and 62 PYR in the control groups. The overall risk reduction 
rate was 55% (relative risk 0.45, 95% CI 0.28–0.71) with consistent results for RCTs. 
Reductions in risk of hip fractures with alendronate treatment were consistent across 
all studies; the P value of consistency is 0.981.   Reproduced with permission from 
Papapoulos SE, Quandt SA, Liberman UA, et al. 2005. Meta-analysis of the efﬁ  cacy of 
alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos 
Int, 16:468–74. Copyright © 2005 Springer International.
Abbreviations: BMD, bone mineral density; CI, conﬁ  dence interval; PYR, person-year 
at risk; RCT, randomized controlled trial.
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postmenopausal women with osteoporosis is supported by a 
report of the World Health Organization (WHO) Scientiﬁ  c 
Group (WHO Scientiﬁ  c Group 2003). RCTs have also dem-
onstrated a similar incidence of gastrointestinal tract adverse 
events in patients treated with alendronate and a placebo, 
with no severe adverse events seen in the alendronate group 
(Liberman et al 1995; Black et al 1996; Cummings et al 
1998). The long-term (10-year) safety of alendronate has 
been conﬁ  rmed (Bone et al 2004; Black et al 2006); reduc-
tions in bone turnover remain stable throughout 10 years 
of alendronate treatment and are associated with continued 
gains in lumbar spine and hip BMD. Moreover, vertebral and 
nonvertebral fracture safety data suggest no loss of beneﬁ  t.
Thus, alendronate could be a candidate for postmeno-
pausal women with osteoporosis who are at a higher risk 
of hip fractures. Vitamin D and calcium supplementation 
would also be needed in patients with vitamin D insuf-
ﬁ  ciency/deﬁ  ciency and low calcium intake. According to 
the analyses of the Fracture Intervention Trial, postmeno-
pausal women treated with alendronate with the greatest 
percentage reduction in bone-speciﬁ  c alkaline phosphatase 
(BSAP) have the lowest risk of hip fractures, while those 
with the smallest reduction in BSAP have the highest risk of 
hip fractures (Figure 2) (Bauer et al 2004). Each 1 standard 
deviation reduction in a 1-year change in BSAP is associ-
ated with 39% fewer hip fractures in alendronate-treated 
postmenopausal women (Bauer et al 2004). Alendronate-
treated postmenopausal women with at least 30% reduc-
tion in BSAP (56% of alendronate-treated subjects) have 
a 74% lower risk of hip fractures relative to those with 
less than 30% (Bauer et al 2004). Alendronate is effec-
tive in reducing the risk of hip fractures across a spectrum 
of ages (Figure 3) (Hochberg et al 2005). The effectiveness 
appears to be greater in patients with a femoral neck BMD 
T score   –2.5 than in patients with a femoral neck BMD 
T score   –2.0 (Hochberg et al 2005).
Adherence of patients 
with alendronate treatment
A retrospective analysis of a large population of new users of 
alendronate with diagnosed osteoporosis has conﬁ  rmed that 
both compliance and persistence, in actual practice, is low 
and inadequate (Rabenda et al 2008). Siris et al (2006) ana-
lyzed the fracture probability across the full range of possible 
compliance values expressed as a medication possession 
ratio (MPR) (full MPR range: 0.0–1.0 or 0%–100%), which 
is deﬁ  ned as the number of days’ supply of a medication with 
Figure 2 One-year change in BSAP and hip fracture risk among alendronate-treated 
postmenopausal women. The data from the FIT, a randomized, double-blind clinical 
trial of 6459 women recruited at 11 US clinical centers, were analyzed. The subjects 
were postmenopausal women (age range: 55–80 years) with femoral neck BMD = 0.68 
g/cm2 (Hologic QDR-2000) who were naïve to bisphosphonate treatment. Percent 
change in BSAP and predicted risk (log odds ratio) of hip fractures (solid line) and 
95% CI (dotted lines) are reported from logistic regression model. Postmenopausal 
women treated with alendronate with the greatest percentage reduction in BSAP had 
the lowest risk of hip fractures, while those with the smallest reduction in BSAP had 
the highest risk of hip fractures. Reproduced from Bauer DC, Black DM, Garnero P, 
et al. 2004. Change in bone turnover and hip, non-spine, and vertebral fracture in 
alendronate-treated women: the fracture intervention trial. J Bone Miner Res, 19:1250–8 
with permission of the American Society for Bone and Mineral Research.
Abbreviations: BMD, bone mineral density; BSAP, bone-speciﬁ  c alkaline phosphatase; 
CI, conﬁ  dence interval; FIT, Fracture Intervention Trial.
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Figure 3 Rates of hip fractures per 10,000 person-years by attained age. A total 
of 18 randomized, placebo-controlled, double-blind, clinical trials of anti-resorptive 
agents that reported both changes in BMD (or BCM) and incidence of non-vertebral 
fractures were identiﬁ  ed from a systematic literature review and from abstracts in 
conference proceedings (Hochberg et al 2005). These studies enrolled 26,494 women 
(age range: 31–85 years) who were naïve to anti-resorptive therapy and accumulated 
a total follow-up of 69,369 women-years, during which 2,415 women experienced 
one or more new nonvertebral fractures. Incidence curves were generated using 
a Cox proportional hazard model of the age-speciﬁ  c hip fracture data. The reduc-
tions in risk of hip fractures among alendronate-treated patients were signiﬁ  cant 
relative to the placebo group for hip fractures; relative risk (95% CI) = 0.47 (0.27, 
0.81). Reproduced from Hochberg MC, Thompson DE, Black DM, et al. 2005. Effect 
of alendronate on the age-speciﬁ  c incidence of symptomatic osteoporotic fractures. 
J Bone Miner Res, 20:971–6 with permission of the American Society for Bone and 
Mineral Research.
Abbreviations: BCM, biochemical marker; BMD, bone mineral density; CI, conﬁ  -
dence interval.
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bisphosphonates during a certain period (Sclar et al 1991). 
At an MPR from 0% to 50%, the probability of fracture 
during a period of 24 months remains consistent at about 
11% and declines progressively once a threshold value of 
50% is achieved (Siris et al 2006). Less than half the women 
were found to be compliant with bisphosphonate therapy 
(MPR   0.8) and approximately 40% of women persisted 
with treatment for 12 months without a substantial gap in 
therapy (Rabenda et al 2008). Poor adherence to alendronate 
treatment is associated with an increased risk of hip fractures 
(Rabenda et al 2008). Thus, adherence (compliance and per-
sistence) with treatment has represented a major challenge 
in patients receiving alendronate.
Once-weekly alendronate, which is the preferred dosing 
regimen, has been reported to be theoretically equivalent to 
daily dosing, providing postmenopausal osteoporotic women 
with a more convenient dosing option that enhances their 
adherence to treatment (Kendler et al 2004; Rossini et al 
2006). Once-weekly alendronate has safety and tolerance 
proﬁ  les similar to daily alendronate in postmenopausal 
women with osteoporosis (Schnitzer et al 2000; Rizzoli et al 
2002; Simon et al 2002).
It has been conﬁ  rmed that compliance with bisphospho-
nate therapy is associated with fracture risk. Rabenda et al 
(2008) have reported that the MPR is a signiﬁ  cant predictor 
of the occurrence of hip fractures in postmenopausal women 
treated with alendronate. The logistic regression model 
has estimated that for each decrease in the MPR of 1%, 
the adjusted risk of hip fractures increases by 0.4%. As 
shown in Figure 4 (Rabenda et al 2008), there is a negative 
estimated linear relationship between the probability of hip 
fractures and the value of the MPR. The treatment regimen 
is also an important determinant of hip fracture occurrence: 
postmenopausal women who receive weekly alendronate are 
16.4% less likely to suffer from hip fractures than those on 
the daily regimen (Rabenda et al 2008).
Rabenda et al (2008) have also shown that persis-
tence to alendronate treatment is a signiﬁ  cant predictor 
of incurring hip fractures. The relative risk reduction for 
hip fractures is 60% for persistent patients compared with 
nonpersistent patients (hazard ratio: 0.404; 95% CI: 0.357, 
0.457; p   0.0001).
Thus, both high compliance and persistence with pre-
scribed osteoporosis medication are signiﬁ  cantly associated 
with reduced hip fracture risk. The once-weekly alendronate 
regimen provides beneﬁ  t in terms of better adherence (com-
pliance and persistence) of the patients to the treatment regi-
men than the once-daily dosing regimen, leading to greater 
efﬁ  cacy against hip fractures.
Mechanism for the efﬁ  cacy
of alendronate against hip fractures
Osteoporosis is deﬁ  ned as a skeletal disorder characterized 
by compromised bone strength, predisposing a person to 
an increased risk of fracture (NIH Consensus Development 
2001). Properties related to bone strength include rate 
of bone turnover, BMD, geometry, microarchitecture, 
and mean degree of mineralization (Epstein 2005). 
Theoretically, microdamage might weaken bone, but no 
relationship to bone strength or fracture risk has been 
established (Epstein 2005).
The proximal femur of the hip is primarily composed 
of cortical bone. In cortical bone, high bone turnover, as 
observed after the menopause, is associated with decreased 
BMD, increased cortical porosity due to increased bone 
remodeling in the Haversian canal, decreased cortical 
thickness due to increased endocortical bone remodeling, 
and decreased mean degree of mineralization (Hedlund 
et al 1989; Bousson et al 2000; Boivin et al 2000; Szulc 
et al 2006). Increased cortical thinning, increased porosity, 
and decreased mean degree of mineralization of bone 
(MDMB) are observed in the cortex in cases of hip fractures 
Figure 4 Probability of hip fractures according to medication possession ratio (MPR). 
A retrospective analysis of a large population of new users of alendronate with diagnosed 
osteoporosis was conducted to investigate adherence to bisphosphonate therapy and 
the impact of adherence on the risk of hip fractures (Rabenda et al 2008). An exhaustive 
search of the Belgian national social security database was conducted. A total of 29,157 
women (age range: 45 years or older) who were naïve to bisphosphonate treatment 
were included for the analysis of compliance (daily group n = 14,136; weekly group 
n = 15,021). The mean MPR at 12 months was 64.7%. There was a negative linear 
estimated relationship between the probability of hip fractures and the value of the 
MPR. Reproduced with permission from Rabenda V, Mertens R, Fabri V, et al. 2008. 
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. 
Osteoporos Int, 19:811–18. Copyright © 2008 Springer International.
Abbreviations: HCI, higher conﬁ  dence interval (upper line); LCI, lower conﬁ  dence 
interval (lower line).
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(Loveridge et al 2004; Bell et al 1999a; Bell et al 1999b; Bell 
1999c), which might be associated with increased indices 
of Haversian remodeling. These changes caused by high 
bone remodeling in terms of high bone turnover translate to 
alterations in bone strength and risk of fractures.
Alendronate inhibits osteoclastic bone resorption, strongly 
reduces bone turnover, increases hip BMD, decreases cortical 
porosity, and produces more uniform mineralization (ie, 
increases the MDMB) in cortical bone, possibly contributing 
to a reduction in the risk of hip fractures (Liberman et al 1996; 
Black et al 1996; Cummings et al 1998; Boivin et al 2000; 
Roschger et al 2001). In alendronate-treated postmenopausal 
women, the distribution of the degree of mineralization 
in cortical bone shows a clear shift toward the highest 
mineralization values and a decrease in the number of bone 
structure units having low values of mineralization (Boivin et al 
2000). The MDMB augmentation probably accounts for most 
of the increase in BMD seen with alendronate (Boivin et al 
2000). According to the hypothesis proposed by Boivin et al 
(2000), the reduction in the activation frequency caused by the 
anti-resorptive effect of alendronate is followed by a prolonged 
secondary mineralization that increases the percentage of bone 
Table 1 Hypothesis proposed by Boivin et al about the potential 
mechanism by which anti-resorptive drugs act on bone remodeling 
and increase the mean degree of mineralization of bone. Repro-
duced with permission from Boivin GY, Chavassieux PM, Santora 
AC, et al. 2000. Alendronate increases bone strength by increasing 
the mean degree of mineralization of bone tissue in osteoporotic 
women. Bone, 27:687–94. Copyright © 2000 Elsevier.
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Figure 5 Percentage change in cross-sectional parameters by hip structure 
analysis. A double-blind, placebo-controlled, randomized clinical single-center trial 
was conducted over 3 years to examine the effect of HRT, ALN, or combina-
tion therapy on hip structure geometry in 373 community-dwelling women (age 
range: 65–90 years) who were naïve to HRT or bisphosphonate treatment. To 
minimize discontinuation after randomization, all participants entered a 3-month, 
open-label run-in phase involving HRT, ALN placebo, and appropriate calcium and 
vitamin D supplementation. Cross-sectional parameters were measured by HSA. 
a: p < 0.05 from baseline, b: p < 0.05 vs placebo, c: p < 0.05 HRT + ALN vs HRT,
d: p < 0.05 HRT + ALN vs ALN, e: p < 0.05 ALN vs HRT. Alendronate improved 
parameters of hip structure geometry as evaluated by the HSA such as cortical 
thickness, cross-sectional area, section modulus, and buckling ratio in the narrow neck 
(A), intertrochanteric region (B), and femoral shaft (C). In addition, improvements of 
the above parameters in the narrow neck and intertrochanteric region were greater 
with combination therapy with HRT. Reproduced from Greenspan SL, Beck TJ, Resnick 
NM, et al. 2005. Effect of hormone replacement, alendronate, or combination therapy 
on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. J 
Bone Miner Res, 20:1525–32 with permission of the American Society for Bone and 
Mineral Research.
Abbreviations: ALN, alendronate; HSA, hip structure analysis; HRT, hormone 
replacement therapy.Clinical Interventions in Aging 2008:3(3) 488
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cortical porosity, improves parameters of hip structure geometry 
(cortical thickness, cross-sectional area, section modulus, and 
buckling ratio), and produces more uniform mineralization 
(increases the MDMB) in cortical bone. A once-weekly alen-
dronate regimen provides better adherence (compliance and 
persistence) of the patients to the treatment than the once-daily 
dosing regimen, leading to greater efﬁ  cacy against hip fractures. 
Thus, the efﬁ  cacy of alendronate against hip fractures has 
been conﬁ  rmed in postmenopausal women with osteoporosis, 
especially with once-weekly dosing regimen.
Abbreviations
BMD, bone mineral density; BSAP, bone-speciﬁ  c alkaline 
phosphatase; HRT, hormone replacement therapy; EBM: 
evidence-based medicine; RCT, randomized controlled 
trial; PYR, person-years at risk; WHO, World Health 
Organization; MPR, medication possession ratio; MDMB, 
mean degree mineralization of bone; DXA, dual-energy 
X-ray absorptiometry; HSA, hip structure analysis.
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structure units having reached a maximum degree of secondary 
mineralization and, though this mechanism, augmentation of 
the MDMB (Table 1).
Recently, it has been possible to extract cross-sectional 
geometry from dual-energy X-ray absorptiometry (DXA) scan 
imaging. Hip structure analysis (HAS) is a computer program 
designed to perform this function with DXA scans of the hip. 
Greenspan et al (2005) have demonstrated that alendronate 
improves parameters of hip structure geometry as evaluated 
by the HAS, such as cortical thickness, cross-sectional area, 
section modulus, and buckling ratio in the narrow neck, inter-
trochanteric region, and femoral shaft (Figure 5) (Greenspan 
et al 2005). These data provide additional information on a 
potential mechanism for hip fracture reduction with alendro-
nate. In addition, improvements in the above parameters in 
the narrow neck and intertrochanteric region are greater in 
combination therapy with HRT (Figure 5) (Greenspan et al 
2005). This result supports the concept that anti-resorptive 
therapies that produce larger decreases in bone turnover 
markers together with larger increases in BMD are associated 
with greater reductions in hip fracture risk, especially at sites 
primarily composed of cortical bone (Hochberg et al 2002).
Osteocyte viability has been observed to be an indicator 
of bone strength, with viability as the result of maintaining 
physiological levels of loading and osteocyte apoptosis as 
the result of a decrease in loading (Epstein 2007). Osteocyte 
apoptosis and decrease are major factors in the bone loss 
and fractures associated with aging (Epstein 2007). A recent 
animal study demonstrated that low doses of risedronate 
or alendronate suppressed osteocyte apoptosis induced by 
fatigue loading of the ulna in rats (Follet 2007). However, 
the effect of alendronate on osteocyte apoptosis remains to 
be established in clinical studies.
Conclusions
Evidence derived from the literature, stratiﬁ  ed and based on strict 
EBM guidelines, suggests the efﬁ  cacy of alendronate against 
hip fractures in postmenopausal women with osteoporosis with 
an overall risk reduction rate of 55%. According to the analyses 
of the Fracture Intervention Trial, each 1 standard deviation 
reduction in a 1-year change in BSAP is associated with 39% 
fewer hip fractures in alendronate-treated postmenopausal 
women, and those with at least a 30% reduction in BSAP have 
a 74% lower risk of hip fractures relative to those with less 
than 30%. Alendronate is effective in reducing the risk of hip 
fractures across a spectrum of ages. The mechanism for this 
anti-fracture efﬁ  cacy has been clariﬁ  ed; alendronate suppresses 
bone turnover and subsequently increases hip BMD, decreases Clinical Interventions in Aging 2008:3(3) 489
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